STOCKS TELEGRAPH

Author: ST Staff

  • Triterras, Inc. (TRIT) Stock on the Rise as it Continues Expansion of Network of Strategic Partners

    Triterras, Inc. (TRIT) stock prices were up 6.32% as of the market close on July 21st, 2021, bringing the price per share up to USD$5.55 at the end of the trading day. Subsequent premarket fluctuations have seen the stock rise by 7.57%, bringing it up to USD$5.97.

    Collaboration with essDOCS

    July 22nd, 2021 saw the leading fintech company for trade and trade finance company announce its collaboration with essDOCS, a global trade management company that prides itself on its paperless operation. The agreement will facilitate the acceleration of the use of digital trade documents for the company’s global community of commodity traders. Aiming to make bulk cargo trading paperless and more efficient, essDOCS allows traders to digitize trade operations and finance processes regardless of cargo type.

    Details of the Agreement

    This is the latest in a string of moves by TRIT to foster growth as it builds out end-to-end services for its online marketplace, which is designed to connect and enable SME businesses, corporates, multinationals, and their lenders to trade online and digitally finance their commodity trading, logistics operations, and supply chains. As per the arrangement, the company will immediately integrate essDOCS’ Cargodocs electronic document capabilities onto Kratos. This will allow the company’s customers to create, review, and approve a paper or electronic bills of lading (eB/L) with their supply chain.

    Increased Visibility

    With the onset of the global coronavirus pandemic having exacerbated shipping costs and delays, there has been increasing awareness on the advantages of fully digitized trading operations. Trade stockholders using essDOCS’ CargoDocs solution, the world’s largest electronic Bill of Lading network, will be able to transfer the eB/L through the trade chain. Transfers can be made between carriers, exporters, financing parties, and importers in as little as three minutes.

    Recent Partnerships

    May 2021 saw the company announce its strategic investment and partnership with Electronic Cash and Payment Solutions, an open banking platform catering to India’s burgeoning Micro and SME marketplace. The series of partnerships have significantly expanded the company’s global footprint with its penetration of the Indian MSME marketplace. The company also recently announced its acquisition of Invoice Bazaar and its partnership with Western Union Business Solutions.

    Future Outlook for TRIT

    Armed with the latest in a growing network of strategic collaborations, TRIT is poised to capitalize on the expanded scope of opportunities made available to it. The company is keen to continue its trajectory of success by further facilitating expansion in its network of partners. Investors are hopeful that management will be able to facilitate significant and sustained increases in shareholder value.

  • Why SigmaTron International, Inc. (SGMA) stock is falling today?

    Shares of the SigmaTron International, Inc. (SGMA) stock were falling in the pre-market trading session today on July 22, 2021. The SGMA stock price saw a decline of 6.99% to drop at $5.06 a share at the time of this writing. In the previous trading session, SGMA stock was green and went high by 7.72% at closing. Let’s discuss more about SigmaTron.

    What’s Happening?

    There seems to be no news related to SigmaTron International in today’s date to justify the bearish sentiment however, SGMA yesterday on July 21, 2021, announced the execution of a definitive agreement and plan of merger with Wagz, Inc which is the privately held pet technology. This merger is the result of the previous announcement that happened last year on  June 4, 2020, in which SGMA stock and Wags, Inc executed the letter of intent in which the proposed business combination was mentioned. This letter of intent has now become the framework for the merger agreement between two parties.

    According to the agreement, the shareholders of Wagz would get 2,443,870 shares issued by SigmaTron which means that the stockholders of Wagz own approximately 28% of SGMA stock and Wagz will operate as the wholly-owned subsidiary of the SigmaTron. It is expected that deal would be closed by the end of September 2021 after reaching certain milestones and meeting the conditions by both parties before closing.

    Forgiveness of $6.3 million loan:

    On July 14, 2021, the SGMA stock did announce the full forgiveness of its Small Business Administration (“SBA”) Paycheck Protection Program loan which was approximately $6.3 million. The forgiveness was received due to  Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) on April 23, 2020. The SGMA stock will do accounting for the forgives in the first quarter of 2022 financial results.

    Financial View of the SGMA stock:

    In the third quarter of 2021 financial results, the revenue was reported $71.5 million compared to $67.4 million in the third quarter of 2020. Net income for the SGMA stock reported $249,268 in the third quarter of 2021 as compared to a net loss of $217,039 in the same tenure of the previous year.

    Conclusion:

    Today’s market sentiment is not in favor of SGMA stock, however, it went high after announcing its recent merger agreement with Wagz, Inc. Recent financial results were positive as compared to the previous year’s same period.

  • TRACON Pharmaceuticals, Inc. (TCON) Stock Plummets Following Upsizing of Underwritten Public Offering

    TRACON Pharmaceuticals, Inc. (TCON) stock prices were down 4.27% as of the market closing on July 21st, 2021, bringing the price per share down to USD$4.93 at the end of the trading day. Subsequent premarket fluctuations saw the stock plummet by 23.33%, bringing it down to USD$3.78.

    Upsizing of Public Offering

    July 21st, 2021 saw the company announce the upsizing of its previously announced public offering as a result of the level of demand. The upsizing will consist of a firm commitment to purchase 3,926,702 shares of common stock, with each share being priced at USD$3.82. Furthermore, the agreement comes equipped with a 30-day option to purchase up to an additional 589,005 shares of common stock at the public offering price. The closing of the public offering is expected to close on July 26th, 2021.

    Details of the Offering

    The public offering is expected to generate gross proceeds in the amount of roughly USD$15 million, before the deduction of expenses related to the offering and excluding the exercising of the over-allotment option. The capital raised is forecasted to be allocated towards the supporting of the continued clinical development of envafolimab, as well as for working capital and general corporate purposes.

    Orphan Drug Designation

    June 29th, 2021 saw the company announce the granting of Orphan Drug Designation to envafolimab by the U.S Food and Drug Administration. The innovative, single-domain antibody against PD-L1 is being developed for the treatment of patients with soft tissue sarcoma. This development followed the submissions of a revised application that consisted of data from the Phase 1 clinical trial from sarcoma patients treated with single-agent envafolimab.

    Basis of Envafolimab ODD

    The Orphan Drug Designation submission for the use of envafolimab in sarcoma included clinical data that signaled confirmed objective partial responses by RECIST with response durations exceeding six months. This promising development was observed in two out of five patients with refractory metastatic alveolar soft part sarcoma (ASPS), with the patients having been administered single-agent envafolimab in Phase 1 clinical trials. The trials were conducted by the company’s partner, 3D Medicines and Alphamab Oncology. The Phase 1 trials did not include patients with undifferentiated pleomorphic sarcoma (UPS) or myxofibrosarcoma (MFS) were not treated as part of Phase 1 trials.

    Future Outlook for TCON

    Armed with the added influx of capital generated from the company’s public offering, TCON is poised to capitalize on the opportunities afforded to it as a result of the granting of Orphan Drug Designation for its flagship treatment. Investors are hopeful that management will be able to facilitate the hasty commercialization and effective proliferation of the treatment as it continues to work closely with the FDA.

  • PBF Energy Inc. (PBF) Stock Undergoes Minor Volatility Following BAAQMD Emissions Ruling

    PBF Energy Inc. (PBF) stock prices were up 8.17% as of the market close on July 21st, 2021, bringing the price per share up to USD$10.46 at the end of the trading day. Subsequent premarket fluctuations saw the stock fall by 2.87%, bringing it down to USD$10.16.

    BAAQMD’s Decision

    July 21st, 2021 saw the company address the BAAQMD Board’s decision to adopt Proposed Amended Rule 6-5, in regard to particulate emission in the Bay Area resulting from refinery Fluid Catalytic Cracking units. The company has been collaborating closely with Bay Area Air Quality Management District staff throughout the rule-making process, which will require refineries to meet a specific emission standard by 2026. Fortunately, this will not require the installation of a wet gas scrubber or other potentially costly technology.

    Implementing Change

    In line with this, the company plans to continue with the implementation of previously planned projects over the upcoming months, which will see the Martinez refinery undergo a drastic reduction in emissions. The company expects to close the gap between existing emissions and target emissions by the first quarter of 2022. PBF is keen to continue partnering with the BAAQMD to facilitate efficient improvements in air quality while ensuring the continued provision of the company’s vital products to one of the largest fuel markets in the world.

    Healthy Financials

    The company exhibited improvements in financial reports for the first quarter of 2021, as compared to the prior quarter. March 2021 indicated a significant increase from January, reflecting favorable market conditions as the ongoing push for universal immunizations resulted in a normalizing and resurgence of demand. Despite this increase, however, the independent refining sector is at the mercy of rising compliance costs under the RFS program.

    Solid Liquidity Position

    As the devastating effects of the pandemic played out following its onset, PBF took measures to protect its balance sheet in the face of economic uncertainty. The company reported having a solid liquidity position of USD$2.3 billion as of March 31st, 2021, of which USD$1.5 billion consisted of cash and funds available via an asset-based lending facility. Furthermore, PBF Logistics LP liquidity included USD$44 million in cash and roughly USD$311 million as a part of a revolving credit facility.

    Future Outlook for PBF

    Armed with a solid liquidity position that will help the company execute their strategy over the next couple months until the economy fully returns to pre-pandemic levels, PBF is poised to capitalize on its opportunities for success. Current and potential investors are hopeful that management will leverage the resources at their disposal to usher in significant and sustained increases in shareholder value.

  • How Is Chembio (CEMI) Stock Skyrocketing 95% in Premarket Session?

    How Is Chembio (CEMI) Stock Skyrocketing 95% in Premarket Session?

    Shares of leading point-of-care diagnostic company focused on infectious diseases Chembio Diagnostics Inc. (CEMI) were trading up 94.66% at $4.01 in premarket trading on Wednesday. Chembio stock decreased -16.26% to end last trading session at $2.06. CEMI stock traded 1.39 million shares on the day, above its average daily trading volume of 0.48 million shares for the previous 50 days.

    In the last five days, CEMI stock share prices have retreated by -20.77; however, over the last month, they have fallen by -32.01%. Over the last three months, CEMI stock price plummeted by 43.25%, and so far this year, it has lost -56.63 percent. After receiving a multimillion-dollar order, CEMI stock has gained traction.

    Who placed the order with CEMI?

    Chembio is one of North America’s leading point-of-care diagnostics companies that specializes in detecting and diagnosing infectious diseases including COVID-19, respiratory disease, and insect-bite diseases. With CEMI’s vast scientific expertise, its novel DPP technology has a wide range of application beyond infectious diseases. Healthcare organizations, physician offices, clinical labs, government agencies, and consumers receive CEMI’s products directly and through distributors globally.

    Yesterday, Chembio announced that it had received a 28.3 million dollar purchase order from Bio-Manguinhos.

    • Chembio’s DPP SARS-CoV-2 Antigen tests for delivery during 2021 were ordered by Bio-Manguinhos to support an urgent need of the Brazilian Ministry of Health to fight the COVID-19 pandemic.
    • The DPP SARS-CoV-2 Antigen test, which uses a nasal swab to detect the antigen, uses a minimally invasive technique to detect COVID-19 infection in only 20 minutes.
    • Chembio’s supply chain, staffing, liquidity, and other matters outside Chembio’s control may prevent CEMI from delivering all the tests on the purchase order.
    • A small drop of blood from the fingertip or alternative samples allows CEMI to provide high-quality, rapid testing results in 15 to 20 minutes.
    • A single patient sample can produce up to eight test results using CEMI’s DPP platform, providing more clinical value than other rapid tests.
    • With CEMI’s highly portable, battery-powered DPP Micro Reader, users can easily and accurately perform certain types of decentralized testing where real-time results can be obtained while patients are still on the spot.
    • Objectivity produces results that reduce the potential for human error that can occur in many rapid tests requiring visual interpretations.

    A worthwhile investment by CEMI:

    Chembio (CEMI) significant expansion of customer relations with Bio-Manguinhos has been encouraging as it addresses COVID-19 testing needs. As a result of this purchase order, CEMI is set to ramp up its production of the DPP SARS-CoV-2 Antigen test, justifying the investments it made earlier in the year.

  • Why Is Datasea (DTSS) Stock Climbing Before the Market Opens?

    Why Is Datasea (DTSS) Stock Climbing Before the Market Opens?

    In pre-market trading hours on Wednesday, shares of the technology company engaged in providing smart security solutions, smart hardware and education-related technologies in China, Datasea Inc. (DTSS) rose 1.82% to $2.79. Last session, Datasea stock fell -37.87% and closed at $2.74. The price range of DTSS stock was $2.69 to $3.799.

    A daily average of 2.08 million shares over the past 100 days was surpassed by 5.12 million shares traded in DTSS. In the last five days, DTSS shares have shed -6.48%, while in the last month they have risen 10.93%.  Following an announcement of a registered direct offering, the DTSS stock is recovering after losing value in the last session.

    DTSS signed an agreement with whom?

    A technology company in China, Datasea offers smart hardware and security solutions. DTSS also develops education-related technologies. To meet the needs of its clients, DTSS uses its proprietary technologies, innovative products, market intelligence, and intellectual property, to deliver comprehensive and optimized security and education solutions.

    The Beijing Science and Technology Commission, Beijing State Taxation Bureau, Beijing Finance Bureau, and Beijing Local Taxation Bureau have jointly certified the DTSS as one of the High Tech Enterprises. DTSS has also been certified as Zhongguancun High Tech Enterprises by the Zhongguancun Science Park Administrative Committee, recognizing the company’s achievement in high technology products.

    In an announcement yesterday, Datasea disclosed that it has signed definitive agreements with certain institution investors for the offering of registered direct securities.

    • The agreement was signed by DTSS for gross proceeds of $8,480,425.92, before commissions and expenses.
    • Assuming all customary closing conditions are met, DTSS anticipates the offering will close on or about July 22, 2021.
    • A registered offering will be conducted by DTSS in which 2,436,904 shares of common stock will be offered at a purchase price of $3.48 per share.
    • DTSS will also offer investors 0.45 unregistered warrants per share of common stock purchased in a private placement.
    • Exercise of the warrants will begin on the date of issuance, expire two and one-half years after issuance, and have an exercise price of $4.48 per DTSS share.
    • In addition to repaying debt, DTSS plans to use the net proceeds for general corporate purposes and working capital.
    • DTSS’ offerings were placed exclusively through FT Global Capital, Inc as its agent.

    Other recent development:

    Datasea announced last week that it had signed six distribution and purchase agreements through its wholly-owned subsidiary Shuhai Zhangxun Information Technology Co., Ltd. Through these agreements, 5G Message-Marketing Cloud Platform (“5G MMCP”) Version 3.0 will be provided, and by adding new district partners, product accessibility in China will be boosted nationwide.

    The six companies that have expressed an interest in 5G Messaging will pay DTSS-subsidiary a combined RMB 886,000 (roughly USD 136,940) for providing their products and services. Datasea (DTSS) subsidiary, Shuhai Zhangxun has already been given RMB 490,400 (about USD 75,776).

  • How Does The Vermilion (VET) Stock Price Increase By 3% Pre-hours?

    How Does The Vermilion (VET) Stock Price Increase By 3% Pre-hours?

    Vermilion Energy Inc. (VET) shares are up 2.68% in pre-market trading at $6.90. Yesterday, Vermilion stock closed at $6.72, up 2.28% or $0.15. Throughout the day, VET shares fluctuated between $6.41 and $6.83. A total of 2,042,000 shares of VET stock were exchanged on the day, a higher volume than the company’s 50-day average of 2,032,000 and lower than its Year-to-date average of 2,412,000. The new additions to the board seem to show that VET stock is continuing to rally after yesterday’s rally.

    Who are the new members of the Vet Team?

    Vermilion operates internationally, acquiring, exploring, developing, and optimizing production assets in North America, Europe, and Australia. In addition to generating free cash flow and returning capital to investors, VET makes value-adding acquisitions. Vet’s operations revolve around the exploration and development of conventional oil and gas resources in North America, as well as in Europe and Australia.

    Vermilion Ms. Manjit Sharma and Ms. Judy Steele were appointed yesterday to Vermilion’s Board of Directors.

    • The expertise Ms. Sharma brings to a variety of industry sectors comes from over 25 years in the field.
    • In her previous role, she led the finance, real estate, procurement, tax, and shared services functions for WSP Canada.
    • From 2007 to 2011, Ms. Sharma served as Vice President, Finance & Shared Services Leader. Since 2016, she has served as the Chief Financial Officer of GE Canada.
    • Prior to joining the company, she has held roles in mergers and acquisitions, tax management, risk management, governance, and diversity and inclusion.
    • Steele was recently the President and Chief Operating Officer of Emera Energy Inc., a leading trading and marketing organization for natural gas and power. Her responsibilities include commercial performance, operations, business growth, risk management, and team development and leadership.
    • In addition to hydro, wind, biomass, and natural gas-fired electrical generating facilities, Ms. Steele has been involved with managing various energy businesses.
    • In addition to being a member of Emera Inc., she also serves on the Emera Board at Leadership Safety Advisory Council, Emera’s sustainability management team, and the company’s corporate leadership team.
    • The previous roles held by Ms. Steele included executive and senior management positions within Emera Inc., including public affairs strategy, media relations, government relations, philanthropy, and investor communications.

    VET will be benefited in what way?

    Ms. Sharma and Ms. Steele were welcomed by VET to become part of its board. With their diverse backgrounds, perspectives and expertise, both newly appointed directors will contribute to Vermilion (VET)’s success.

  • What Caused The MARA Stock To Rise Premarket?

    What Caused The MARA Stock To Rise Premarket?

    The shares of one of the largest enterprise Bitcoin mining companies in North America, Marathon Digital Holdings Inc. (MARA) rose 8.26% to trade at $24.50 in pre-market trading at the last check. Marathon Digital stock rose 1.25% to $22.63 by close on Tuesday. In the past 50 days, MARA stock volume averaged 13.27 million shares per day, but today’s volume was lower at 6.29 million shares.

    Within the last 12 months, MARA shares have gained 2346.49%, but they have fallen by -12.83% in the last week. A three-month period has seen MARA stock drop by -32.59%, while a six-month period has seen it increase by 1.25%. The market value of MARA sits at $2.37 billion and the outstanding stock was 94.35 million total shares. A report about its participation in a digital event sparked a rally in MARA stock.

    What event will MARA participate in?

    Marathon Digital is a digital asset technology company that mines cryptocurrencies and generates digital assets in the United States through blockchain technology. In February 2021, Marathon Digital Holdings, Inc. changed its name from Marathon Patent Group, Inc. Las Vegas-based MARA was founded in 2010 and has its headquarters there.

    The Mining Disrupt Conference, to be held in Miami, Florida on July 20-21, 2021, will be attended by Marathon Digital.

    • A gathering of blockchain mining professionals and innovators is taking place at Mining Disrupt.
    • In his presentation, the CEO of MARA, Fred Thiel, will talk about “Vertical Integration or Maximum Agility – Which Strategy Will Be Best for Mining in the Next 4 Years?”
    • The presentation will begin at 10:50 am Eastern time on Wednesday, July 21st.
    • On that same day, the CEO of MARA will also participate in two separate panels entitled “Should Miners Form Councils – Does It Work for or Against Decentralization?” and “Dear Elon (…)”.
    • Participants can register for the event at https://miningdisrupt.com.

    Charlie Schumacher has been appointed director of corporate communications at Marathon Digital, the company announced last Wednesday. Schumacher will report to MARA’s CEO and be responsible for MARA’s investor relations, public relations, and marketing efforts.

    What caused MARA to appoint Schumacher?

    In light of the increasing institutional adoption of Bitcoin, MARA’s expanding operations, and the goal of establishing Marathon as one of the most prominent Bitcoin miners in North America, Marathon believes it is the right time to hire an in-house corporate communications director to elevate the organization. In September 2020, Schumacher began working for Marathon Digital (MARA) and has proved to be a valuable asset. The new and expanded position he holds will enable MARA to benefit from his expertise.

  • hift4 Payments Inc. (FOUR) Stock Drop In Afterhours Session. How Did That Happen?

    hift4 Payments Inc. (FOUR) Stock Drop In Afterhours Session. How Did That Happen?

    Yesterday, Shift4 Payments Inc. (FOUR) fell on the charts, as it closed at $85.98 down -6.22% in after-hours trading. During the regular session on Tuesday, Shift4 closed at $91.68 gaining 4.16%. During the day, 699,000 Shift4 shares were traded, which is below the average volume of 846.14K shares seen over the past three months. The Shift4 stock fluctuated between $88.14 and $93.20 during the trading session.

    An EPS ratio of -0.58 was recorded for Shift4. Within the last five trading sessions, Shift4 stock has lost -4.71%, while over the past month it has lost -6.90%. Year-to-date, Shift4 stock has gained 21.59%. With a 50-day moving average of $93.43, Shift4’s 200-day moving average is 78.49. Furthermore, Shift4 is currently trading at an RSI of 44.47. In response to its announcements of offering common stock as well as convertible notes, Shift4 stock plummeted.

    What will Shift4’s share offering look like?

    With a complete ecosystem of solutions that extends beyond payments to include a range of value-added services, Shift4 is an independent provider of integrated payment processing and technology solutions. In addition to providing technology to over 350 software providers, Shift4’s technologies are used by companies in many industries, including hospitality, retail, food, and beverage, e-commerce, lodging, gaming, among others. More than 200,000 businesses used Shift4 in 2019 to process more than 3.5 billion transactions securely. Shift4 currently has over 7,000 sales partners.

    Earlier yesterday, Shift4 announced that it planned to sell 1,791,818 shares of its Class-A common stock through an underwritten public offering (the “Primary Offering”). There are also plans by Searchlight Capital Partners, LP, and certain entities related to it (the “selling stockholders”) to offer for sale 5,208,182 shares of Shift4’s Class A common stock.

    The underwriters will also be given the option to purchase an additional 1,050,000 shares of Shift4’s Class A common stock within 30 days of the offering. In this offering, Shift4 intends to use its net proceeds from the primary offering to buy LLC interests from Shift4 Payments, LLC at a price per unit of the publicly traded Class A common stock less underwriting discounts.

    Another Shift4 move is:

    Shift4 announced its intention, in a separate press release, to offer a $500.0 million aggregate principal amount of convertible senior notes due 2027 (the “Notes”). It is also expected that Shift4 (FOUR) will grant the initial purchasers of the Notes an option to purchase the Notes up to an additional $75.0 million aggregate principal amount within 13 days of the Notes being issued.

  • Is This Why The Opiant (OPNT) Stock Rose In Extended Session?

    Is This Why The Opiant (OPNT) Stock Rose In Extended Session?

    Shares of the specialty pharmaceutical company developing medicines to treat addictions and drug overdose, Opiant Pharmaceuticals Inc. (OPNT) gained 5.20% to $18.00 in Tuesday’s after-hours trading. In the morning session, Opiant stock gained 4.27% to finish at $17.11. There were 58042 shares traded for OPNT stock, a volume which was below the average daily trading volume of 0.17 million shares published for the last 50 days.

    Over the last five days, OPNT stock has declined 3.63%; however, over the last month, it has gained 23.09%. This year, the price of OPNT stock has risen 81.63 percent and has surged by 62.18% over the last three months. As a result of the news of its grant of inducement awards to new employees, OPNT stock surged.

    How did OPNT grant the award?

    Pharmaceutical company Opiant Pharmaceuticals develops medicine to treat drug overdoses and addictions. As a treatment for opioid overdoses, OPNT provides NARCAN nasal spray, an opioid-reversing treatment. Products that are in OPNT’s pipeline include treatments for opioid overdose reversal, alcohol use disorders, acute cannabinoid overdoses, and opioid use disorders. The company used to be known as Lightlake Therapeutics Inc. and since January 2016 has changed its name to Opiant Pharmaceuticals, Inc.

    Opiant Pharmaceuticals announced yesterday it had granted incentive awards to two new employees, an announcement made by OPNT in compliance of Nasdaq Market rules.

    • In an action approved by its Compensation Committee, OPNT Board of Directors granted a non-qualified stock option.
    • A grant of restricted stock units covering 15,000 shares of common stock along with an option to purchase 50,000 shares of OPNT common stock.
    • OPNT granted it as an inducement incentive to Matthew Ruth, its new Chief Commercial Officer, for his acceptance of employment with the Company in accordance with Nasdaq listing rules.
    • A further 6,500 shares of OPNT common stock and restricted stock units were approved by the Committee as additional non-qualified stock options.
    • A total of 3,200 shares of OPNT common stock will be delivered as a material incentive to another new employee joining the organization.

    Terms under which OPNT will execute the options:

    The exercise price for OPNT options is $16.41, which is the closing price of Opiant’s common stock on the Nasdaq Stock Market on July 19, 2021, the grant date. A restricted stock unit award will vest over a four-year period, with 25% vesting on the one-year anniversary of the grant date and the subsequent 25% vesting each subsequent anniversary of the grant date, provided an employee remains employed by Opiant (OPNT) through these vesting dates. OPNT’s existing Inducement Plan, as well as the stock option contract among employees and restricted stock unit contracts between employees, governs the exercise of stock options and the award of restricted stock units.